FDA Approves Supplement for Butalbital, Aspirin, Caffeine, and Codeine Phosphate
The FDA has approved a supplemental application for a combination product containing butalbital, aspirin, caffeine, and codeine phosphate.
Company
Pharmaceutical intelligence for LGM Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.